News

New Report Shows CRC Screening Rates Increased When a Medically Underserved Population is Offered Epi proColon Blood Test

Berlin (Germany) and San Diego, CA (U.S.A.), May 20, 2019 – Epigenomics AG (FSE: ECX, OTCQX: EPGNY; the “Company”), a molecular diagnostics company focused on blood-based detection of cancers using its proprietary DNA methylation biomarker technology, today reported new results that underscore Epi proColon(R) colorectal cancer’s (CRC) high acceptance rate compared with stool-based screening tests…

Read More

Vela Diagnostics Submits NGS HIV Genotyping, Drug Resistance Assay to FDA

NEW YORK (GenomeWeb) Mar 26, 2019 – Vela Diagnostics has submitted a next-generation sequencing (NGS) assay that detects HIV-1 drug resistance mutations (DRMs) to the US Food and Drug Administration (FDA), the company announced today. The Sentosa SQ HIV Genotyping Assay can be used on plasma samples from patients with HIV-1 infection to detect HIV-1…

Read More

Curetis and Menarini Diagnostics Enter into Strategic Pan-European Exclusive Partnership for the Distribution of Curetis’ Unyvero

Menarini Diagnostics to distribute Unyvero Platform and application cartridges in numerous European countries Menarini Diagnostics to deploy its commercial team for the marketing of Unyvero Platform across Europe Partnership to be launched at ECCMID 2019 in Amsterdam Amsterdam, the Netherlands, and Holzgerlingen, Germany, March 26, 2019, 08:00 am CET – Curetis N.V. (the “Company” and,…

Read More

U.S. Representatives Payne, Marchant, and Sewell Introduce Bi-Partisan Colorectal Cancer Detection Bill

Berlin (Germany) and San Diego, CA (U.S.A.), March 15, 2019 – Representatives Donald Payne, Jr. (D-NJ) and Kenny Marchant (R-TX) today introduced the ”Donald Payne Sr. Colorectal Cancer Detection Act” to the United States House of Representatives in Washington D.C. This House Bill aims to provide payment and coverage under the Medicare program for FDA-approved…

Read More

Curetis’ Subsidiary Ares Genetics and QIAGEN Enter into Bioinformatics Partnership to Fight Antimicrobial Resistance

February 18, 2019, 22:00 CET – Curetis N.V. (the “Company” and together with its subsidiaries “Curetis”), a developer of next-level molecular diagnostic solutions, today announced that its wholly-owned subsidiary Ares Genetics GmbH (Vienna, Austria) and QIAGEN N.V. (NYSE: QGEN; Frankfurt Prime Standard: QIA) have entered into a strategic licensing agreement for ARESdb and AREStools in…

Read More

Curetis Partner Beijing Clear Biotech Submits Filing for Unyvero Approval in China

Amsterdam, the Netherlands, and Holzgerlingen, Germany, February 04, 2019, 08:00 am CET – Curetis N.V. (the “Company” and, together with its subsidiaries, “Curetis”), a developer of next-level molecular diagnostic solutions, today announced that Beijing Clear Biotech (BCB) has filed for regulatory approval of the Unyvero A50 HPN Application Cartridge for pneumonia with the Chinese National…

Read More

Curetis Unyvero Application Cartridges Receive Regulatory Approvals in Malaysia and Thailand

Amsterdam, the Netherlands, and Holzgerlingen, Germany, January 30, 2019; published at 08:00 a.m. CET — Curetis N.V. (the “Company” and, together with Curetis GmbH, “Curetis”), a developer of next-level molecular diagnostic solutions, today announced that its partner for the commercialization of Unyvero in the ASEAN region, Acumen Research Laboratories Pte Ltd. (Acumen), has received first…

Read More

Curetis Subsidiary Ares Genetics Advances AI-powered Infectious Disease and Antibiotic Resistance Test

Ares Genetics to start EUR 1.3 million TRIPLE-A development project co-funded by Vienna Business Agency Initiates set-up of R&D and service laboratory in Vienna Vienna, Austria, Holzgerlingen, Germany, and Amsterdam, The Netherlands; January 08, 2019; published at 08:00 am CET – Curetis N.V. (the “Company” and, together with its subsidiaries, “Curetis”), a developer of next-level…

Read More

Curetis Subsidiary Ares Genetics Teams Up with Leading Global Pharma Company in Fight Against Antibiotic Resistance

> Strategic collaboration agreement with Sandoz to develop digital anti-infectives platform > Collaboration leverages Ares Genetics’ antibiotic resistance database ARESdb > Short-term focus on repurposing existing antibiotics to treat infections with multi drug resistant pathogens Vienna, Austria, Holzgerlingen, Germany and Amsterdam, The Netherlands; December 18, 2018; published at 08:00 am CET – Curetis N.V. (the…

Read More